Applied AI Breakthroughs

AI drug discovery draws major investment, awaits clinical proof

AI drug discovery draws major investment, awaits clinical proof

Isomorphic Labs’ $5 billion round signals major commitment to AI-designed drug candidates, but recent coverage still reports no named candidate, registered trial, or patient dosing. Tesorai’s $5.3 million raise targets biological-data infrastructure and cites a p-tau217 finding across five Alzheimer’s studies; clinical impact remains unestablished.

Sources (4)
Updated Nov 19, 2026